Interleukin 6 in cerebrospinal fluid is a biomarker for delayed cerebral ischemia (DCI) related infarctions after aneurysmal subarachnoid hemorrhage

Interleukin 6 (IL-6) is a prominent proinflammatory cytokine and has been discussed as a potential biomarker for delayed cerebral ischemia (DCI) following aneurysmal subarachnoid hemorrhage. In the present study we have analyzed the time course of serum and cerebrospinal fluid (CSF) IL-6 levels in 82 patients with severe aneurysmal subarachnoid hemorrhage (SAH) requiring external ventricular drains in correlation to angiographic vasospasm, delayed cerebral ischemia, secondary infarctions and other clinical parameters. We observed much higher daily mean IL-6 levels (but also large interindividual variations) in the CSF than the serum of the patients with a peak between days 4 and 14 including a maximum on day 5 after SAH. Individual CSF peak levels correlated significantly with DCI (mean day 4-14 peak, DCI: 26,291 +/- 24,159 pg/ml vs. no DCI: 16,184 +/- 13,163 pg/ml; P=0.023). Importantly, CSF IL-6 levels differed significantly between cases with DCI and infarctions and patients with DCI and no infarction (mean day 4-14 peak, DCI with infarction: 37,209 +/- 26,951 pg/ml vs. DCI, no infarction: 15,123 +/- 11,239 pg/ml; P=0.003), while findings in the latter patient group were similar to cases with no vasospasm (mean day 4-14 peak, DCI, no infarction: 15,123 +/- 11,239 vs. no DCI: 15,840 +/- 12,979; P=0.873). Together, these data support a potential role for elevated CSF IL-6 levels as a biomarker for DCI with infarction rather than for DCI in general. This fits well with a growing body of evidence linking neuroinflammation to ischemia and infarction, but (together with the large interindividual variations observed) limits the diagnostic usefulness of CSF IL-6 levels in SAH patients.

Automated summary

The study observed that peak levels of IL-6 in the cerebrospinal fluid (CSF) of patients with severe aneurysmal subarachnoid hemorrhage (SAH) occurred between days 4 and 14 after SAH, with significant correlations to delayed cerebral ischemia (DCI) and infarctions. Elevated CSF IL-6 levels may serve as a potential biomarker for DCI with infarction, but individual variations limit its diagnostic utility in SAH patients.